FUNDAMENTALS · Fundamentals · US Healthcare

Hyperfine (HYPR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Hyperfine (HYPR) is a US-listed Healthcare company in Medical - Specialties with a market capitalization of $82M, trading at $0.98 on the NASDAQ. This SniperIQ fundamentals page covers Hyperfine's valuation, profitability (net margin -226.9%), revenue (

4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$82M
Net Margin-226.9%
Revenue (FY25)
4M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Hyperfine's market cap?

Hyperfine (HYPR) has a market capitalization of approximately $82M, trading at $0.98 on the NASDAQ. Market cap moves with the live share price.

What is Hyperfine's P/E ratio?

Hyperfine's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Hyperfine?

Hyperfine runs a net profit margin of -226.9%, a gross margin of 51.2%, and an operating margin of -226.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Hyperfine generate?

Hyperfine reported revenue of

4M for fiscal year 2025, with net income of -
6M and earnings per share (EPS) of -0.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Hyperfine pay a dividend?

Hyperfine does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Hyperfine financially healthy?

Hyperfine carries a debt-to-equity ratio of 0.39x and a current ratio of 5.52x, with a market beta of 1.40. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Hyperfine a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hyperfine (HYPR) the key facts are: market cap $82M, revenue

4M, 52-week range 0.85-2.22. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Hyperfine's full fundamentals live

Get Hyperfine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Champions Oncology (CSBR) fundamentals · Prescient Therapeutics (PTX) fundamentals · Oncolytics Biotech (ONCY) fundamentals · vTv Therapeutics (VTVT) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons